Product information and disease descriptionProduct descriptionProduct information
Dosage forms and strengths
1 evidence topic · 1 source
Investigational cell suspension
Deramiocel-specific material safety data sheet
No evidence found.
Deramiocel (CAP-1002)
Duchenne muscular dystrophy
- Manufacturer
- Capricor Therapeutics
- Regulatory submission
- Class 2 BLA resubmission submitted February 2026
- Launch
- Not announced
- Last updated